Exoestrogens: Mechanisms of action and strategies for identification and assessment

Environmental Toxicology and Chemistry

Volumn 17, Issue 1, 1998, Pages 3-14

  Gillesby, Bradley E ^a   Zacharewski, Timothy R ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Michigan State University   (United States)

Author keywords

2,3,7,8 Tetrachlorodibenzo p dioxin; Dioxin; Environmental estrogen; Estrogen receptor; Exoestrogen

Indexed keywords

ARYL HYDROCARBON RECEPTOR; DIOXIN; ENDOCRINE; ENVIRONMENTAL CONTAMINANT; ESTROGEN RECEPTOR; EXOESTROGEN;

AROMATIC HYDROCARBONS; DRUG THERAPY; ENDOCRINOLOGY; FURAN RESINS; GENES; HAZARDOUS MATERIALS; PHYSIOLOGY; POLYCHLORINATED BIPHENYLS; PROTEINS;

HORMONES;

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR; CELL NUCLEUS RECEPTOR; DIOXIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FURAN DERIVATIVE; POLYCHLORINATED BIPHENYL; SEX HORMONE;

BINDING AFFINITY; CANCER; CANCER INCIDENCE; ENDOCRINE SYSTEM; ESTROGEN METABOLISM; GENE EXPRESSION REGULATION; HEREDITY; HORMONE DEPENDENCE; POLLUTANT; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0031984291     PISSN: 07307268     EISSN: None     Source Type: Journal    
DOI: 10.1897/1551-5028(1998)017<0003:EMOAAS>2.3.CO;2     Document Type: Review

References (172)

1. Safe SH. 1995. Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol Ther 67:247-281.
2. Davis DL, Bradlow HL. 1995. Can environmental estrogens cause breast cancer? Sci Am 273:167-172.
3. Ahlborg UG, et al. 1995. Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: An assessment of the biological and epidemiological evidence. Crit Rev Toxicol 25:463-531.
4. Guillette LJ, Jr, Gross TS, Masson GR, Matter JM, Percival HF, Woodward AR. 1994. Developmental abnormalities of the gonad and abnormal sex hormone concentrations in juvenile alligators from contaminated and control lakes in Florida. Environ Health Perspect 102:680-688.
5. Guillette LJ, Jr, Pickford DB, Crain DA, Rooney AA, Percival HF. 1996. Reduction in penis size and plasma testosterone concentrations in juvenile alligators living in a contaminated environment. Gen Comp Endocrinol 101:32-42.
6. McLachlan JA, Arnold SF. 1996. Environmental estrogens: Found internally, certain compounds are important signals; found in the environment, they can become just so much noise. Am Sci 84:452-461.
7. McLachlan JA, Newbold RR, Shah HC, Hogan MD, Dixon RL. 1982. Reduced fertility in female mice exposed transplancentally to diethystilbestrol (DES). Fertil Steril 38:364-371.
8. McLachlan JA, Newbold RR, Bullock BC. 1980. Long-tern effects on the female mouse genital tract associated with prenatal exposure to diethylstilbestrol. Cancer Res 40:3988-3999.
9. Garcia-Rodriguez J, et al. 1996. Exposure of pesticides and crytorchidism: Geographical evidence of a possible association. Environ Health Perspect 104:1090-1095.
10. Sharpe RM, Skakkebaek NE. 1993. Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 341:1392-1395.
11. Carlsen E, Giwercman A, Keiding N, Skakkebaek NE. 1995. Declining semen quality and increasing incidence of testicular cancer: Is there a common cause? Environ Health Perspect 103:137-139.
12. Wine RN, Li L-H, Barnes LH, Gulati DK, Chapin RE. 1997. Reproductive toxicity of di-n-butylphthalute in a continuous breeding protocol in Sprague-Dawley rats. Environ Health Perspect 105:102-107.
13. Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM. 1995. Persistent DDT metabolite p,p′-DDE is a potent androgen receptor antagonist. Nature 375:581-585.
14. Grandjean P, et al. 1996. Impact of endocrine disrupters on human health and wildlife. Workshop, European Workshop on the Impact of Endocrine Disrupters on Human Health and Wildlife, Weybridge, UK, December 2-4, p 5.
15. Gray LE, et al. 1996. Endocrine screening methods. Workshop, Endocrine Screening Methods, Durham, NC, USA. July 14-15.
16. Mangelsdorf DJ, et al. 1995. The nuclear receptor superfamily: The second decade. Cell 83:835-839.
17. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23:1686-1690.
18. Montano MM, Muller V, Trobaugh A, Kutzenellenbogen BS. 1995. The carboxy-terminal F domain of the human estrogen receptor: Role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol 9:814-825.
19. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA. 1992. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 6:1634-1641.
20. Truss M, Beato M. 1993. Steroid hormone receptors: Interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 14:459-479.
21. Mader S, Chambon P, White JH. 1993. Defining a minimal estrogen receptor DNA binding domain. Nucleic Acids Res 21:1125-1132.
22. White TE, Gasiewicz TA. 1993. The human estrogen receptor structural gene contains a DNA sequence that binds activated mouse and human Ah receptors: A possible mechanism of estrogen receptor regulation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Biophys Res Commun 193:956-962.
23. Baumann H, Hard T. 1995. Structural characterization of a short peptide fragment that mediates estrogen-receptor dimerization. Eur J Biochem 230:879-885.
24. Metzger D, All S, Bornert JM, Chambon P. 1995. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J Biol Chem 270:9535-9542.
25. Webster NJ, Green S, Jin JR, Chambon P. 1988. The hormone- binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54:199-207.
26. Webster NJ, Green S, Tasset D, Ponglikitmongkol M, Chambon P. 1989. The transcriptional activation function located in the hormone-binding domain of the human oestrogen receptor is not encoded in a single exon. EMBO J 8:1441-1446.
27. Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P. 1989. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J 8:1981-1986.
28. Tora L, White J, Brou C, Tasset D, Webster N, Scheer E, Chambon P. 1989. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59:477-487.
29. Parker MG, Arbuckle N, Dauvois S, Danielian P, White R. 1993. Structure and function of the estrogen receptor. Ann NY Acad Sci 684:119-126.
30. Ekena K, Weis KE, Katzenellenbogen JA, Katzenellenbogen BS. 1996. Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding. J Biol Chem 271:20053-20059.
31. Glass CK. 1994. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr Rev 15:391-407.
32. Akner G, Wikstrorn AC, Gustafsson JA. 1995. Subcellular distribution of the glucocorticoid receptor and evidence for its association with microtubules. J Steroid Biochem Mol Biol 52:1-16.
33. Yang J, DeFranco DB. 1996. Assessment of glucocorticoid receptor-heat shock protein 90 interactions in vivo during nucleo-cytoplasmic trafficking. Mol Endocrinol 10:3-13.
34. Parker KL, Schimmer BP. 1994. The role of nuclear receptors in steroid hormone production. Sem Cancer Biol 5:317-325.
35. Smith DF, Toft DO. 1993. Steroid receptors and their associated proteins. Mol Endocrinol 7:4-11.
36. Segnitz, B, Gehring U. 1995. Subunit structure of the nonacti- vated human estrogen receptor. Proc Natl Acad Sci USA 92:2179-2183.
37. Glass CK, Rose DW, Rosenfeld MG. 1997. Nuclear receptor coactivators. Curr Opin Cell Biol 9:222-232.
38. Horwitz KB, Jackson TA, Rain DL, Richer JK, Takimoto GS, Tung L. 1996. Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167-1177.
39. Katzenellenbogen JA. 1995. The structural pervasiveness of estrogenic activity. Environ Health Perspect 103:99-101.
40. Meek MD, Clemons JH, Wu ZF, Zacharewski TR. 1997. Assessment of the alleged estrogen-receptor mediated activity of eight commercial phthalate esters. Fundam Appl Toxicol 36:295.
41. Jobling S, Reynolds T, Whitte R, Parker MG, Sumpter JP. 1995. A variety of environmentally persistent chemicals, including some phthalate plasticizers are weakly estrogenic. Environ Health Perspect 103:582-587.
42. Vonier PM, Crain DA, McLachlan JA, Guillette LJ, Jr, Arnold SF. 1996. Interaction of environmental chemicals with the estrogen and progesterone receptors from the oviduct of the American alligator. Environ Health Perspect 104:1318-1322.
43. Sumpter JP, Jobling S. 1995. Vitellogenesis as a biomarker for estrogenic contamination of the aquatic environment. Environ Health Perspect 103:173-178.
44. Arnold SF, Klotz DM, Collins BM, Vonier PM, Guillette LJ, Jr, McLachlan JA. 1996. Synergistic activation of estrogen receptor with combinations of environmental chemicals. Science 272:1489-1492.
45. Feldman D, Krishnan A. 1995. Estrogens in unexpected places: Possible implications for researchers and consumers. Environ Health Perspect 103:129-133.
46. Bradlow HL, Davis DL, Lin G, Sepkovic D, Tiwari R. 1995. Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: A biologic marker of breast cancer risk. Environ Health Perspect 103:147-150.
47. Wolff MS, Toniolo PG. 1995. Environmental organochlorine exposure as a potential etiologic factor in breast cancer. Environ Health Perspect 103:141-145.
48. Adami HO, et al. 1995. Organochlorine compounds and estrogen-related cancers in women. Cancer Causes Control 6:551-566.
49. Fry DM. 1995. Reproductive effects in birds exposed to pesticides and industrial chemicals. Environ Health Perspect 103:165-171.
50. Moore M, et al. 1997. Antiestrogenic activity of hydroxylated polychlorinated biphenyl congeners identified in human serum. Toxicol Appl Pharmacol 142:160-168.
51. Connor K, et al. 1997. Hydroxylated polychlorinated biophenyls (PCBs) as estrogens and antiestrogens: Structure-activity relationships. Toxicol Appl Pharmacol 145:111-123.
52. Klotz DM, Beckman BS, Hill SM, McLachlan JA, Walters MR, Arnold SF. 1996. Identification of environmental chemicals with estrogenic activity using a combination of in vitro assays. Environ Health Perspect 104:1084-1089.
53. Balaguer P, Joyeux A, Denison MS, Vincent R, Gillesby BE, Zacharewski T. 1996. Assessing the estrogenic and dioxin-like activities of chemicals and complex mixtures using in vitro recombinant receptor-reporter gene assays. Can J Physiol Pharmacol 74:216-222.
54. Ruh MF, Zacharewski T, Connor K, Howell J, Chen I, Safe S. 1995. Naringenin: A weakly estrogenic bioflavonoid that exhibits antiestrogenic activity. Biochem Pharmacol 50:1485-1493.
55. Adlercreutz H. 1995. Phytoestrogens: Epidemiology and a possible role in cancer protection. Environ Health Perspect 103:103-112.
56. Makela S, Santti R, Salo L, McLachlan JA. 1995. Phytoestrogens are partial estrogen agonists in the adult male mouse. Environ Health Perspect 103:123-127.
57. Mayr U, Butsch A, Schneiders. 1992. Validation of two in vitro systems for estrogenic activities with zearalenone, phytoestrogens and cereal extracts. Toxicology 74:135-149.
58. Pagliacci MC, Smacchia M, Migliorati G, Grignani F, Riccardi C, Nicoletti I. 1994. Growth-inhibitory effects of the natural phyto-oestrogen genistein in MCF-7 human breast cancer cells. Eur J Cancer 30A:1675-1682.
59. Green S. 1990. Modulation of oestrogen receptor activity by oestrogens and anti-oestrogens. J Steroid Biochem Mol Biol 37:747-751.
60. Newbold R. 1995. Cellular and molecular effects of developmental exposure to diethylstilbestrol: Implications for other environmental estrogens. Environ Health Perspect 103:83-87.
61. Zacharewski TR, Berhane K, Gillesby BE, Burnison BK. 1995. Detection of estrogen- and dioxin-like activitiy in pulp and paper mill black liquor and effluent using in vitro recombinant receptor/reporter gene assays. Environ Sci Technol 29:4140-4146.
62. Haney AF, Hammond CB, Soules MR, Creasman WT. 1979. Diethylstilbestrol-induced upper genital tract abnormalities. Fertil Steril 31:142-146.
63. Newbold RR, McLachlan JA. 1982. Vaginal adenosis and adenocarcinoma in mice exposed prenatally or neonatally to diethylstilbestrol. Cancer Res 42:2003-2011.
64. Iguchi T, Fukazawa Y, Bern HA. 1995. Effects of sex hormones on oncogene expression in the vagina and on development of sexual dimorphism of the pelvis and anococcygeus muscle in the mouse. Environ Health Perspect 103:79-82.
65. McLachlan JA, Newbold RR, Bullock B. 1975. Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. Science 190:991-992.
66. McLachlan JA. 1977. Prenatal exposure to diethylstilbestrol in mice: Toxicological studies. J Toxicol Environ Health 2:527-537.
67. Wilcox AJ, Baird DD, Weinberg CR, Hornsby PP, Herbst AL. 1995. Fertility in men exposed prenatally to diethylstilbestrol. N Engl J Med 332:1411-1416.
68. Woodward AR, Percival HF, Jennings ML, Morre CT. 1993. Low clutch viability of American alligators on Lake Apopka. Fla Sci 56:52-63.
69. Bitman J, Cecil HC, Harris SJ, Fries GF. 1969. Estrogenic actvitiy of o,p′-DDT in the mammalian uterus and avian oviduct. Science 162:371-372.
70. Fry DM, Toone CK. 1981. DDT-induced feminization of gull embryos. Science 213:922-924.
71. Crews D. 1994. Temperature, steroids, and sex determination. J Endocrinol 142:1-8.
72. Crews D, Bergeron JM, Flores D, Bull JJ, Skipper JK, Tousignant A, Wibbels T. 1994. Temperature-dependent sex determination: Proximate mechanisms, functional outcomes, and practical applications. Dev Genet 15:297-312.
73. Bergeron JM, Crews D, McLachlan JA. 1994. PCBs as environmental estrogens: Turtle sex determination as a biomarker of environmental contamination. Environ Health Perspect 102:780-781.
74. Crews D, Bergeron JM, McLachlan JA. 1995. The role of estrogen in turtle sex determination and the effect of PCBs. Environ Health Perspect 103:73-77.
75. Arnold SF, McLachlan JA. 1996. Synergistic signals in the environment. Environ Health Perspect 104:1020-1023.
76. Arcaro KF, Gierthy JF. 1997. Estrogenic responses of human breast cancer cells to combinations of hydroxylated PCBs, pesticides and 17β-estradiol. Fundam Appl Toxicol 36:295.
77. Ramamoorthy K, Wang F, Chen I-C, Maness SC, Leonard L, Gaido K, Safe S. 1997. Estrogenic activities of 2′,3′,4′,5′-tetrachloro- and 2′,4′,6′-trichloro-4-biphenylol: No synergistic interactions. Fundam Appl Toxicol 36:295.
78. Safe S, et al. 1997. Estrogenic activity of a dieldrin/toxaphene mixture in the mouse uterus, MCF-7 human breast cancer cells and yeast-based eslrogen receptor assays: No apparent synergism. Fundam Appl Toxicol 36:294.
79. Wiese TE, Lambright CR, Kelce WR. 1997. Lack of synergistic estrogen effects of dieldrin and endosulfan mixtures on MCF-7 and MVLN cells. Fundam Appl Toxicol 36:294.
80. Migliaccio S, Newbold RR, McLachlan JA, Korach KS. 1995. Alterations in estrogen levels during development affects the skeleton: Use of an animal model. Environ Health Perspect 103:95-97.
81. Migliaccio S, Newbold RR, Bullock BC, McLachlan JA, Korach KS. 1992. Developmental exposure to estrogens induces persistent changes in skeletal tissue. Endocrinology 130:1756-1758.
82. Hammond GL, Bocchinfuso WP. 1995. Sex hormone-binding globulin/androgen-binding protein: Steroid-binding and dimerization domains. J Steroid Biochem Mol Biol 53:543-552.
83. Joseph DR. 1994. Structure, function, and regulation of andro- gen-binding protein/sex hormone-binding globulin. Vitam Horm 49:197-280.
84. Rosner W. 1990. The functions of corticosteroid-binding globulin and sex hormone-binding globulin: Recent advances. Endocr Rev 11:80-91.
85. Hammond GL. 1990. Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins. Endocr Rev 11:65-79.
86. Gaido KW, Leonard LS, Lovell S, Gould JC, Babai D, Portier CJ, McDonnell DP. 1997. Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicol Appl Pharmacol 143:205-212.
87. Christman JK, Nehls S, Polin L, Brooks SC. 1995. Relationship between estrogen structure and conformational changes in estrogen receptor/DNA complexes. J Steroid Biochem Mol Biol 54:201-210.
88. Metzger D, Berry M, Ali S, Chambon P. 1995. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo. Mol Endocrinol 9:579-591.
89. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. 1996. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93:5925-5930.
90. Mosselman S, Polman J, Dijkema R. 1996. ER-beta - Identification and characterization of a novel human estrogen receptor FEBS Lett 392:49-53.
91. Segars JH, et al. 1993. Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: Evidence for multiple inhibitory pathways. Mol Cell Biol 13:2258-2268.
92. Keller H, Givel F, Perroud M, Wahli W. 1995. Signaling cross-talk between peroxisome proliferator-activatedreceptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol 9:794-804.
93. Nunez SB, Medin JA, Keller H, Wang K, Ozato K, Wahli W, Segars J. 1995. Retinoid X receptor beta and peroxisome proliferator-activated receptor activate an estrogen response element. Recent Prog Horm Res 50:409-416.
94. Weigel NL. 1996. Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319:657-667.
95. Engelberg D, Klein C, Martinetto H, Struhl K, Karin M. 1994. The UV response involving the Ras signaling pathway and AP-1 transcription factors is conserved between yeast and mammals. Cell 77:381-390.
96. Mahon MJ, Gasiewicz TA. 1995. Ah receptor phosphorylation: Localization of phosphorylation sites to the C-terminal half of the protein. Arch Biochem Biophys 318:166-174.
97. Ignar-Trowbridge DM, Pimentel M, Teng CT, Korach KS, McLachlan JA. 1995. Cross talk between peptide growth factor and estrogen receptor signaling systems. Environ Health Perspect 103:35-38.
98. Bunone G, Briand PA, Miksicek RJ, Picard D. 1996. Activation of the unliganded estrogen receptor by EGF involves the map kinase pathway and direct phosphorylation. EMBO J 15:2174-2183.
99. Pietras RJ, et al. 1995. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446.
100. O'Malley BW, Schrader WT, Mani S, Smith C, Weigel NL, Conneely OM, Clark JH. 1995. An alternative ligand-independent pathway for activation of steroid receptors. Recent Prog Harm Res 50:333-347.
101. Patrone C, Ma ZQ, Pollio G, Agrati P, Parker MG, Maggi A. 1996. Cross-coupling between insulin and estrogen receptor in human neuroblastoma cells. Mol Endocrinol 10:499-507.
102. Pestell RG, Albanese C, Watanabe G, Johnson J, Eklund N, Lastowiecki P, Jameson JL. 1995. Epidermal growth factor and c-Jun act via a common DNA regulatory element to stimulate transcription of the ovine P-450 cholesterol side chain cleavage (CYP11A1) promoter. J Biol Chem 270:18301-18308.
103. King CM. 1995. Tamoxifen and the induction of cancer. Carcinogenesis 16:1449-1454.
104. Jordan VC. 1995. Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 208:144-149.
105. Love RR. 1989. Tamoxifen therapy in primary breast cancer: Biology, efficacy, and side effects. J Clin Oncol 7:803-815.
106. Zacharewski TR, Bondy KL, McDonell P, Wu ZF. 1994. Antiestrogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17 beta-estradiol-induced pS2 expression. Cancer Res 54:2707-2713.
107. Astroff B, Safe S. 1991. 6-Alkyl-1,3,8-trichlorodibenzofurans as antiestrogens in female Sprague-Dawley rats. Toxicology 69:187-197.
108. Astroff B, Eldridge B, Safe S. 1991. Inhibition of the 17 beta-estradiol-induced and constitutive expression of the cellular protooncogene c-fos by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the female rat uterus. Toxicol Lett 56:305-315.
109. Biegel L, Safe S. 1990. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on cell growth and the secretion of the estrogen-induced 34-, 52- and 160-kDa proteins in human breast cancer cells. J Steroid Biochem Mol Biol 37:725-732.
110. Astroff B, Rowlands C, Dickerson R, Safe S. 1990. 2,3,7,8-Tetrachlorodibenzo-p-dioxin inhibition of 17 beta-estradiol-induced increases in rat uterine epidermal growth factor receptor binding activity and gene expression. Mol Cell Endocrinol 72:247-252.
111. Spink DC, Lincoln DW, Dickerman HW, Gierthy JF. 1990. 2,3,7,8-Tetrachlorodibenzo-p-dioxin causes an extensive alteration of 17 beta-estradiol metabolism in MCF-7 breast tumor cells. Proc Natl Acad Sci USA 87:6917-6921.
112. Zacharewski T, Harris M, Biegel L, Morrison V, Merchant M, Safe S. 1992. 6-Mclhyl-1,3,8-trichlorodibenzofuran (MCDF) as an antiestrogen in human and rodent cancer cell lines: Evidence for the role of the Ah receptor. Toxicol Appl Pharmacol 113:311-318.
113. Kharat I, Saatcioglu F. 1996. Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen receptor - Cross-talk between aryl hydrocarbon- and estrogen-mediated signaling. J Biol Chem 271:10533-10537.
114. Chaloupka K, Krishnan V, Safe S. 1992. Polynuclear aromatic hydrocarbon carcinogens as antiestrogens in MCF-7 human breast cancer cells: Role of the Ah receptor. Carcinogenesis 13:2233-2239.
115. Hankinson O. 1995. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 35:307-340.
116. Spink DC, et al. 1992. 17 Beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: A comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem Biophys 293:342-348.
117. Spink DC, Hayes CL, Young NR, Christou M, Sutler TR, Jefcoate CR, Gierthy JF. 1994. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: Evidence for induction of a novel 17 beta-estradiol 4-hydroxylase. J Steroid Biochem Mol Biol 51:251-258.
118. Zacharewski T, Harris M, Safe S. 1991. Evidence for the mechanism of action of the 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated decrease of nuclear estrogen receptor levels in wild-type and mutant mouse Hepa 1c1c7 cells. Biochem Pharmacol 41:1931-1939.
119. Safe S, Astroff B, Harris M, Zacharewski T, Dickerson R, Romkes M, Biegel L. 1991. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) and related compounds as antioestrogens: Characterization and mechanism of action. Pharmacol Toxicol 69:400-409.
120. Gierthy JF, Spink BC, Figge HL, Pentecost BT, Spink DC. 1996. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 12-O-tetradecanoylphorbol-13-acetate and 17-beta-estradiol on estrogen receptor regulation in Mcf-7 human breast cancer cells. J Cell Biochem 60:173-184.
121. Rubin M, et al. 1994. 9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res 54:6549-6556.
122. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. 1995. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669.
123. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR. 1990. Transcription factor interactions: Selectors of positive or negative regulation from a single DNA element. Science 249:1266-1272.
124. Miner JN, Diamond MI, Yamamoto KR. 1991. Joints in the regulatory lattice: Composite regulation by steroid receptor-AP1 complexes. Cell Growth Differ 2:525-530.
125. Stein B, Yang MX. 1995. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 15:4971-4979.
126. Savouret JF, et al. 1994. Interplay between estrogens, progestins, retinoic acid and AP-1 on a single regulatory site in the progesterone receptor gene. J Biol Chem 269:28955-28962.
127. Horvai AE, et al. 1997. Nuclear integration of Jak/Stat and Ras/ Ap-1 signaling by CBP and P300. Proc Natl Acad Sci USA 94:1074-1079.
128. Levine M, Manley JL. 1989. Transcripitonal repression of eukaryotic promoters. Cell 59:405-408.
129. Lee MO, Liu Y, Zhang XK. 1995. A retinoic acid response element that overlaps an estrogen response element mediates multihormonal sensitivity in transcriptional activation of the lactoferrin gene. Mol Cell Biol 15:4194-4207.
130. Kraus WL, Weis KE, Katzenellenbogen BS. 1995. Inhibitory cross-talk between steroid hormone receptors: Differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol Cell Biol 15:1847-1857.
131. Krishnan V, Wang X, Safe S. 1994. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 269:15912-15917.
132. Gillesby BE, Stanostefanos M, Safe S, Wu Z-F, Zacharewski TR. 1997. Identification of a motif within the 5′ regulatory region of pS2 which is responsible for AP-1 binding and TCDD-mediated suppression. Biochemistry 36:6080-6089.
133. Krishnan V, Porter W, Santostefano M, Wang X, Safe S. 1995. Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells. Mol Cell Biol 15:6710-6719.
134. Masten SA, Shiverick KT. 1995. The Ah receptor recognizes DNA binding sites for the B cell transcription factor. BSAP: A possible mechanism for dioxin-mediated alteration of CD 19 gene expression in human B lymphocytes. Biochem Biophys Res Commun 212:27-34.
135. Zacharewski T. 1997. In vitro bioassays for assessing estrogenic substances. Environ Sci Technol 31:613-623.
136. Reel JR, Lamb IJ, Neal BH. 1996. Survey and assessment of mammalian estrogen biological assays for hazard characterization. Fundam Appl Toxicol 34:288-305.
137. Rubin BL, Dorfman AS, Black L, Dorfman RI. 1951. Bioassay of estrogens using the mouse uterine response. Endocrinology 49:429-439.
138. Dorfman RI, Dorfman AS. 1954. Estrogen assays using the rat uterus. Endocrinology 55:65-69.
139. Hisaw FL. 1959. Comparative effectiveness of estrogens on fluid imbibition and growth of the rat's uterus. Endocrinology 54:276-289.
140. Jones RC, Edgren RA. 1973. The effects of various steroids on the vaginal histology in the rat. Fertil Steril 24:284-291.
141. Martin L, Claringbold PJ. 1960. The mitogenic action of oestrogens in the vaginal epithelium of the ovariectomized mouse. J Endocrinol 20:173-186.
142. Ruh TS, Katzenellenbogen BS, Katzenellenbogen JA, Gorski J. 1973. Estrone interaction with the rat uterus: In vitro response and nuclear uptake. Endocrinology 92:125-134.
143. Gorski J, Raker B. 1974. Estrogen action in the uterus: The requisite for sustained estrogen binding in the nucleus. Gynecol Oncol 2:249-258.
144. Soto AM, Sonnenschein C. 1985. The role of estrogens on the proliferation of human breast tumor cells (MCF-7). J Steroid Biochem 23:87-94.
145. Gierthy JF, Lincoln DW, Roth KE, Bowser SS, Bennett JA, Bradley L, Dickerman HW. 1991. Estrogen-stimulation of postconfluent cell accumulation and foci formation of human MCF-7 breast cancer cells. J Cell Biochem 45:177-187.
146. Heppell SA, Denslow ND, Folmar LC, Sullivan CV. 1995. Universal assay of vitellogenin as a biomarker for environmental estrogens. Environ Health Perspect 103:9-15.
147. Gillesby BE, Zacharewski T. 1997. The use of quantitative RT-PCR to examine the effects of endocrine disrupting chemicals on the expression of the human breast cancer prognostic marker, pS2. Fundam Appl Toxicol 36:130.
148. Metzger D, White JH, Chambon P. 1988. The human oestrogen receptor functions in yeast. Nature 334:31-36.
149. Connor K, et al. 1996. Failure of chloro-S-triazine-derived compounds to induce estrogen receptor-mediated responses in vivo and in vitro. Fundam Appl Toxicol 30:93-101.
150. Cavailles V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ, Parker MG. 1995. Nuclear factor RIP 140 modulates transcriptional activation by the estrogen receptor. EMBO J 14:3741-3751.
151. Cavailles V, Dauvois S, Danielian PS, Parker MO. 1994. Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 91:10009-10013.
152. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. 1994. Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription. Science 264:1455-1458.
153. Landel CC, Kushner PJ, Greene GL. 1995. Estrogen receptor accessory proteins: Effects on receptor-DNA interactions. Environ Health Perspect 103:23-28.
154. Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF, McLachlan JA, Korach KS. 1992. Coupling of dual signaling pathways: Epidermal growth factor action involves the estrogen receptor. Proc Natl Acad Sci USA 89:4658-4662.
155. Jordan VC. 1995. Tamoxifen: Toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol 35:195-211.
156. Wright CD, Compston JE. 1995. Tamoxifen: Oestrogen or antioestrogen in bone? Q J Med 88:307-310.
157. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W. 1995. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA 92:4206-4210.
158. Kociba RJ, et al. 1978. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol Appl Pharmacol 46:279-303.
159. Gierthy JF, Bennett JA, Bradley LM, Cutler DS. 1993. Correlation of in vitro and in vivo growth suppression of MCF-7 human breast cancer by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res 53:3149-3153.
160. Romkes M, Piskorska-Pliszczynska J, Safe S. 1987. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on hepatic and uterine estrogen receptor levels in rats. Toxicol Appl Pharmacol 87:306-314.
161. Romkes M, Safe S. 1988. Comparative activities of 2,3,7,8-tetrachlorodibenzo-p-dioxin and progesterone as antiestrogens in the female rat uterus. Toxicol Appl Pharmacol 92:368-380.
162. Astroff B, Safe S. 1990. 2,3,7,8-Tetrachlorodibenzo-p-dioxin as an antiestrogen: Effect on rat uterine peroxidase activity. Biochem Pharmacol 39:485-488.
163. Merchant M, Krishnan V, Safe S. 1993. Mechanism of action of alpha-naphthoflavone as an Ah receptor antagonist in MCF-7 human breast cancer cells. Toxicol Appl Pharmacol 120:179-185.
164. Harper N, Wang X, Liu H, Safe S. 1994. Inhibition of estrogen- induced progesterone receptor in MCF-7 human breast cancer cells by aryl hydrocarbon (Ah) receptor agonists. Mol Cell Endocrinol 104:47-55.
165. Gierthy JF, Lincoln DW, Gillespie MB, Seeger JI, Martinez HL, Dickerman HW, Kumar SA. 1987. Suppression of estrogen-regulated extracellular tissue plasminogen activator activity of MCF-7 cells by 2,3,7,8-teirachlorodibenzo-p-dioxin. Cancer Res 47:6198-6203.
166. Moore M, Narasimhan TR, Wang X, Krishnan V, Safe S, Williams HJ, Scott AI. 1993. Interaction of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 12-O-tetradecanoylphorbol-13-acetate (TPA) and 17 beta-estradiol in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol 44:251-261.
167. Narasimhan TR, Safe S, Williams HJ, Scott AI. 1991. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17 beta-estradiol-induced glucose metabolism in MCF-7 human breast cancer cells: 13C nuclear magnetic resonance spectroscopy studies. Mol Pharmacol 40:1029-1035.
168. Liu H, Safe S. 1996. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDDJ on insulin-induced responses in MCF-7 human breast cancer cells. Toxicol Appl Pharmacol 138:242-250.
169. Liu H, Biegel L, Narasimhan TR, Rowlands C, Safe S. 1992. Inhibition of insulin-like growth factor-I responses in MCF-7 cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Mol Cell Endocrinol 87:19-28.
170. Fernandez P, Burghardt R, Smith R, Nodland K, Safe S. 1994. High passage T47D human breast cancer cells: Altered endocrine and 2,3,7,8-tetrachlorodibenzo-p-dioxin responsiveness. Eur J Pharmacol 270:53-65.
171. Fernandez P, Safe S. 1992. Growth inhibitory and antimitogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in T47D human breast cancer cells. Toxicol Lett 61:185-197.
172. Dohr O, Vogel C, Abel J. 1994. Modulation of growth factor expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Exp Clin Immunogenet 11:142-148.